A novel nitro-substituted seco-CI: Application as a reductively activated adept prodrug
- 19 November 1996
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 6 (22) , 2741-2744
- https://doi.org/10.1016/s0960-894x(96)00508-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductaseBioorganic & Medicinal Chemistry Letters, 1995
- Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductaseBiochemical Pharmacology, 1995
- Synthesis and Antitumor Activity of Duocarmycin Derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1995
- Antibody-Directed Enzyme Prodrug TherapyClinical Pharmacokinetics, 1994
- Self-Immolative Prodrugs: Candidates for Antibody-Directed Enzyme Prodrug Therapy in Conjunction with a Nitroreductase EnzymeJournal of Medicinal Chemistry, 1994
- Design of Antitumor Prodrugs: Substrates for Antibody Targeted EnzymesChemical Reviews, 1994
- Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugatesTrends in Biotechnology, 1994
- The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)Cancer and Metastasis Reviews, 1993
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—II: A comparison of an Escherichia coli nitroreductase and Walker DT diaphoraseBiochemical Pharmacology, 1992
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—IBiochemical Pharmacology, 1992